Neurol. praxi. 2017;18(1):25-31 | DOI: 10.36290/neu.2017.129

Chemotherapy-induced polyneuropathy

MUDr. Jana Raputová^{1, 2}, MUDr. Eva Vlčková, Ph.D.^{1, 2}, MUDr. Lenka Šmardová³, MUDr. Aneta Rajdová^{1, 2,}, doc. MUDr. Andrea Janíková, Ph.D.³

1Neurologická klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice Brno, 2CEITEC – Středoevropský technologický institut, Masarykova univerzita, Brno, 3Interní hematologická a onkologická klinika FN Brno a Lékařské fakulty Masarykovy univerzity Brno

Chemotherapy-induced polyneuropathy belongs to frequent adverse effects of anticancer chemotherapy with a significant negative

influence on patients` daily living and social activities. Neuropathy is axonal, affects large and/or small nerve fibers (based

on particular drug) and causes sensory, motor and/or autonomic symptoms and signs. The most important neurotoxic agents

are platinum derivatives, taxoids, vinca alkaloids, thalidomide and proteasome inhibitors. CIPN is usually at least partly reversible,

however, some drugs can damage nerve fibres irreversibly, e.g. thalidomid. CIPN prevention is mainly based on appropriate indication

of neurotoxic drugs considering preexisting polyneuropathy and its risk factors. If the polyneuropathy occurs during the

anticancer treatment, dose reduction or change of anticancer treatment can prevent further worsening of the peripheral nerve

impairment.

Keywords: polyneuropathies, antineoplastic agents, cisplatin, taxoids, vinca alkaloids, proteasome inhibitors

Received: September 24, 2019; Accepted: October 8, 2019; Prepublished online: October 8, 2019; Published: March 1, 2017  Show citation